LSC17评分在急性髓系白血病中补充遗传学和可测量残留病:一项ALFA研究
在ALFA-0702试验中前瞻性治疗的504例成人AML患者中分析LSC17。LSC17高状态与较低完全缓解率(OR 0.41,P=0.0007)、较短总生存(3年OS 70.0% vs 52.7%,P<0.0001)和无病生存(HR 1.36,P=0.048)相关。在123例NPM1突变AML完全缓解患者中,LSC17高状态独立预测较差DFS(HR 2.34,P=0.01)。LSC17低状态且NPM1-MRD阴性者占48%,3年OS自CR起为93.1%,对比LSC17高状态和/或NPM1-MRD阳性者60.7%(P=0.0001)。
要点
- LSC17高状态与较低完全缓解率(OR 0.41,P=0.0007)和较短总生存(3年OS 70.0% vs 52.7%,P<0.0001)相关。
- 在多变量分析中,LSC17高状态与较短无病生存相关(HR 1.36,P=0.048)。
- 在NPM1突变AML完全缓解患者中,LSC17高状态独立预测较差无病生存(HR 2.34,P=0.01)。
核心结论
- LSC17评估可细化接受强化治疗的成人AML患者的遗传学风险分层。
- LSC17联合MRD可识别NPM1突变AML中临床结局极佳的患者亚群。
研究设计与样本
- 在ALFA-0702试验中前瞻性治疗的504例成人AML患者中分析LSC17。
- 在123例NPM1突变AML完全缓解患者中分析LSC17与NPM1-MRD。
主要发现
- RUNX1或TP53突变与较高LSC17评分相关,CEBPA和NPM1突变与较低评分相关。
- 多变量分析中,LSC17高状态与较低完全缓解率相关(OR 0.41,P=0.0007),校正ELN22、年龄和白细胞计数。
- LSC17高状态与较短总生存相关(3年OS 70.0% vs 52.7%,P<0.0001)。
- 多变量分析中,LSC17高状态与较短无病生存相关(HR 1.36,P=0.048),校正ELN22、年龄和白细胞计数。
- 在123例NPM1突变AML完全缓解患者中,LSC17高状态预测较差无病生存(HR 2.34,P=0.01),独立于年龄、白细胞计数、ELN22风险和NPM1-MRD。
关键数值与推荐
- LSC17高状态完全缓解的多变量OR为0.41(P=0.0007)。
- LSC17高状态3年OS为70.0%,LSC17低状态为52.7%(P<0.0001)。
- LSC17高状态无病生存多变量HR为1.36(P=0.048)。
- NPM1突变AML完全缓解患者中LSC17高状态无病生存HR为2.34(P=0.01)。
- LSC17低状态且NPM1-MRD阴性者3年OS自CR起为93.1%,对比LSC17高状态和/或NPM1-MRD阳性者60.7%(P=0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Whether the LSC17 gene expression can improve risk stratification in the context of next generation sequencing-based risk stratification and measurable residual disease (MRD) in patients with intensively treated AML has not been explored. We analyzed LSC17 in 504 adult patients prospectively treated in the ALFA-0702 trial. RUNX1 or TP53 mutations were associated with higher LSC1 scores while CEBPA and NPM1 mutations were associated with lower scores. Patients with high LSC17 scores had a lower rate of complete response (CR) in a multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European LeukemiaNet 2022 (ELN22), age, and white blood cell count (WBC). LSC17-high status was associated with shorter overall survival (OS) (3-year OS: 70.0% vs 52.7% in patients with LSC17-low status; P < .0001). In a multivariable analysis considering ELN22, age, and WBC, patients with LSC17-high status had shorter disease-free survival (DFS) (hazard ratio [HR], 1.36; P = .048) than those with LSC17-low status. In 123 patients with NPM1-mutated AML in CR, LSC17-high status predicted poorer DFS (HR, 2.34; P = .01), independent of age, WBC, ELN22 risk, and NPM1-MRD. LSC-low status and negative NPM1-MRD identified a subset comprising 48% of patients with mutated NPM1 with a 3-year OS from CR of 93.1% compared with 60.7% in those with LSC17-high status and/or positive NPM1-MRD (P = .0001). Overall, LSC17 assessment refines genetic risk stratification in adult patients with AML treated intensively. Combined with MRD, LSC17 identifies a subset of patients with NPM1-mutated AML with excellent clinical outcome.
引用
- Vasseur L, Fenwarth L, Lambert J, et al. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study. Blood Adv. 2023. PMID: 37205853. doi:10.1182/bloodadvances.2023010155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。